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S100B promotes development and maturation in the mammalian brain. However, prolonged or extensive exposure can lead
to neurodegeneration. Two important functions of S100B in this regard, are its role in the development and plasticity of the
serotonergic neurotransmitter system, and its role in the cascade of glial changes associated with neuroinﬂammation. Both of
theseprocessesarethereforeacceleratedtowardsdegenerationindiseaseprocesseswhereinS100Bisincreased,notably,Alzheimer’s
disease(AD)andDownsyndrome(DS).InordertostudytheroleofS100Binthiscontext,wehaveexaminedS100Boverexpressing
transgenic mice. Similar to AD and DS, the transgenic animals show a profound change in serotonin innervation. By 28 weeks of
age, there is a signiﬁcant loss of terminals in the hippocampus. Similarly, the transgenic animals show neuroinﬂammatory changes
analogous with AD and DS. These include decreased numbers of mature, stable astroglial cells, increased numbers of activated
microglial cells and increased microglial expression of the cell surface receptor RAGE. Eventually, the S100B transgenic animals
show neurodegeneration and the appearance of hyperphosphorylated tau structures, as seen in late stage DS and AD. The role of
S100B in these conditions is discussed.
1.Introduction
S100B is a member of the EF-hand type of calcium binding
S100 protein family which consists of approximately 20
diﬀerent proteins. S100B is the only member found on
chromosome 21, the remaining largely being found in a
cluster on chromosome 1. S100B is the principle S100
found in brain, and makes up approximately 0.5% of all
brain proteins. Under normal physiological states, S100B
is expressed predominantly in astroglial cells of the central
nervous system (CNS), and also to a lesser extent, in
neurons, microglia, and oligodendrocytes [1–7]. However,
in neuropathological conditions, including those induced by
environmentalstressors,infection,ischemia,trauma,psychi-
atric conditions such as depression [8–10], and schizophre-
nia [11, 12], the cellular and tissue distribution of S100B
within the brain may change. As a brain-derived protein
measurable in peripheral samples, S100B is often used as a
biochemical marker for brain injury. In the periphery, S100B
is expressed by Schwann cells, ependymocytes, adipocytes,
chondrocytes, melanocytes, dendritic cells, skeletal muscles,
and myocardium [13]. The fact that S100B is increased in
a wide variety of pathological conditions is indicative of the
diverse functions that this protein plays throughout the body
and brain [14, 15].
Donato has suggested that S100B is important for the
progression of cells through the cell cycle [16, 17]. We have
used the term, “accelerated aging,” to describe cell cycle
changes in the CNS. Regardless of the term employed, the
message is the same: S100B acts in the brain to promote
development and aid in recovery, but also as an inﬂamma-
tory protein with a role in aging and neuropathology.2 Cardiovascular Psychiatry and Neurology
Serum levels of S100B in humans are age-dependent
[18] being highest in newborn, stable throughout adulthood
and increasing again in aging. A similar proﬁle is seen
in rodents [19]. It has been suggested that the increased
S100B in aging is related to a lifetime of proinﬂammatory
events, including ischemia, trauma, and infections. The
eﬀects of S100B in brain are not only age-dependent, they
are also concentration-dependent, such that it is protective
and trophic at low concentrations [20], but toxic and
proapoptotic at high concentrations [21, 22].
The neurobiological eﬀects of S100B are known to occur
intracellularly, in the cells which express the proteins, as
well as extracellularly, as the protein can be released, notably
in response to serotonin (5-HT) binding to the 5-HT1A
receptor [16, 17, 23]. In addition to 5-HT, other factors
known to stimulate S100B release include IL-6, adenosine,
glutamate and cannabinoid receptors [24–26]. There is also
a substantial amount of passive release into the neuropil.
Some of the detrimental extracellular eﬀects of S100B
may be mediated via the cell-surface receptor for advanced
glycation end-products (RAGE). In the central nervous
system, RAGE can be localized to neurons, microglial
cells, and astrocytes. The RAGE receptor is a member
of the immunoglobulin superfamily and leads to cellular
dysfunction in a number of disorders. This receptor was
originally identiﬁed and characterized for its binding of
advanced glycation end-products (AGEs) which accumulate
in diseases such as diabetes and renal failure [27]. More
recently, RAGE was shown to be a multiligand, cell-surface
receptor, responding to a number of ligands, including
S100B. It is interesting to note that increased S100B results in
increased RAGE [28]. Consistent with this notion is the fact
that during development, or following an insult, both S100B
and RAGE increase whereas in normal adult tissue, relatively
low RAGE expression is found.
ElevatedbrainS100Bexpressionoccursinvariousdisease
states, including Alzheimer’s disease (AD) and Down syn-
drome (DS). The gene for S100B is found on chromosome
21 and is often part of the triplicated chromosome in DS.
Interestingly, Down Syndrome almost inevitably leads to
an extremely early development of AD and the increase in
S100B is thought to contribute to the pathology of both.
Although S100B has a variety of cellular eﬀects throughout
the body and brain, its role in neuroinﬂammation, and
in the regulation and maintenance of the serotonergic
nervous system is highlighted, with a particular focus on
the hippocampus. Understanding neuroinﬂammation and
serotonin neuronal plasticity in this brain region may help to
explain many ﬁndings of changes in learning and memory,
as well as the occurrence of depression symptoms. This
is especially pertinent when considering co-morbidity in
conditions wherein the levels of S100B are altered, such as
AD and DS.
1.1. Alzheimer’s Disease. Numerous human postmortem
studies have shown increased S100B in the brain of subjects
with AD [29–31]. This elevated S100B correlates with many
of the neuropathological changes, including the presence of
beta-amyloid plaques and neuroﬁbrillary tangles. Elevated
S100B has also been found in the cerebrospinal ﬂuid of
AD patients [32] and correlates with the degree of brain
atrophy [33]. In a transgenic mouse model of amyloid
pathology, increasing S100B has been shown to increase
plaque formation [34]. Little work has been done on the
role which S100B overexpression might directly play in the
formation of neuroﬁbrillary tangles. However, one recent
study showed that S100B acts through the RAGE receptor
to result in hyperphosphorylated tau, a contributor to
neuroﬁbrillary tangles [35]. In the current review, data have
been included showing hyperphosphorylated tau in S100B
overexpressing mice. Thus, chronic overexpression of S100B
may lead to both plaque and tangle formation.
1.2. Down Syndrome. Serum levels of S100B are greatly
increased in Down syndrome [36] and postmortem brain
studies show lifelong overexpression of the protein [37, 38].
As in AD, many of the neuropathological changes in DS are
thoughttoberelatedtotheoverexpressionofS100B[39,40].
Previous studies have shown behavioral, neuropathologi-
cal and cardiovascular alterations in a transgenic mouse
overexpressing human S100B protein which we use in our
studies [40–46]. These mice were designed to model the
elevated S100B that is often a part of the Down syndrome
genotype [47]. Similar to DS patients who almost inevitably
show premature signs of aging and AD, the S100B mice
show signs of accelerated aging [48], neuropathology [44,
46, 49], and behavioral deﬁcits [42, 43]. Thus, the S100B
transgenic mouse is well-suited to study the inﬂuence of
chronic S100B over-expression on brain and behavior in the
context of DS, including the accelerated development of AD
neuropathology.
2. S100B andSerotoninNeuroplasticity
The neurons which produce serotonin are amongst the
earliest developing neurons in the mammalian brain and
serotonin plays a role in the development and maturation of
many brain regions [50]. Serotonin also becomes the most
widely-distributed system throughout the cortex, touching
on virtually every neuron in cortex [51]. This widespread
distribution and early development allows for a role for
serotonin in maintaining and promoting synaptic plasticity.
Much of this eﬀect of serotonin is mediated through the
release of S100B. During development, S100B promotes
process outgrowth from cortical cells [52, 53]a sw e l l
as promoting dendritic development in the hippocampus
[54]. A reciprocal relationship occurs, whereby serotonin
(through 5-HT1A receptors) not only releases S100B [55,
56], but S100B also promotes development of serotonin
terminals. Treatment with drugs and agents which increase
serotonin, such as MDMA [57], or selective serotonin
reuptake inhibitors [19, 58], increase the expression of
S100B. Thus, S100B levels are important in regulating the
terminaloutgrowthandmaintenanceofserotoninterminals.
Interestingly, by twenty years of age, PET studies in nor-
mal populations have shown that the serotonin transporterCardiovascular Psychiatry and Neurology 3
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Figure 1: Serotonergic ﬁber analysis in the hippocampus of normal and S100B transgenic mice. In (a), a graph of the mean cycloid crosses
(cm2/cm3) is shown to indicate the results from the stereological analysis showing a signiﬁcant increase (P<. 05) of SERT ﬁbers in the
dentate gyrus of 10-week-old S100B transgenic mice. Alternatively, at 28 weeks, signiﬁcantly less (P<. 05) SERT ﬁbers were observed in the
dentate gyrus of S100B transgenic mice. In (b), the results from the densitometric analysis are shown in areas CA1, CA3, and Lacunosum
Moleculare of the hippocampus from 28-week-old mice. Note that there is a signiﬁcant decrease (∗P = .027) in the density of serotonergic
ﬁbers in the S100B transgenic mice. It is pertinent to note that this densitometric method was veriﬁed in the infrapyramidal blade, where
the results were consistent with the stereological analysis. There were no signiﬁcant diﬀerences at the 10 week timepoint (data not shown)
in CA1, CA3, or Lacunosum Moleculare. In (c) and (d), representative photomicrographs from the infrapyramidal blade of 28-week-old
control (c) and S100B transgenic (d) mice. Note the apparent decreased density of serotonergic ﬁbers in the S100B transgenic mice (d).
begins to decrease and continues to do so at the approximate
rate of 10% per decade up until the 8th decade [59]. A
further loss with aging may increase if S100B increases. For
example, in neurodegenerative disease, such as Parkinson’s
disease and frontal lobe dementia, the forebrain serotonin
ﬁbers are decreased and become dystrophic, with enlarged
and bulbous endings [60].
In midgestation DS fetuses, there is a signiﬁcant (40%)
loss of serotonin content in frontal cortex [61], although
thereisnolossofterminaldevelopment[62].Assubjectsage,
pronounced region-speciﬁc changes in serotonin terminal
areas are seen. In the adult, loss of serotonin content is seen
in caudate and temporal cortex, but increases are found in
occipital cortex [63]. Studies of the serotonin terminal den-
sity, show that adult DS have increased terminals in frontal
cortex [64]. Unfortunately, there are no reported studies on
serotonincontentorterminaldensityinhippocampusofDS,
o fw h i c hw ea r ea w a r e .
The increased levels of S100B in Alzheimer’s disease may
also be associated with a loss of serotonin. Neuroﬁbrillary
tangles have been shown to occur in the raphe nuclei, the
site of serotonergic cell bodies [65, 66], and there is a loss
of serotonin terminals in hippocampus and several other
subcortical and cortical structures [67–71].
We have examined the development and maintenance of
serotonin terminals in the S100B overexpressing transgenic
mouse using an antibody raised against the serotonin trans-
porter (SERT) which stains serotonergic ﬁbers. Our results
show increased serotonergic ﬁbers in the dentate gyrus of
the hippocampus of 10 week old S100B transgenic mice.
Conversely, at 28 weeks, there is an accelerated loss of SERT-
stained serotonin ﬁbers as these animals age (Figure 1).4 Cardiovascular Psychiatry and Neurology
(a)
5-HT positive cells in the raphe nucleus
0
20
40
60
80
100
120
140
160
180
C
e
l
l
s
p
e
r
s
l
i
c
e
Dorsal raphe Median raphe Caudolinear
raphe
CD1
S100B
(b)
Figure 2: Serotonin cells in the raphe nucleus of 7-month-old control and S100B transgenic mice. In (a), a representative photomicrograph
is shown to illustrate the 5-HT immunohistochemical labeling of serotonin cells in the raphe nuclei. In (b), a graph of the means showing
no signiﬁcant diﬀerences in the number of serotonin neurons between CD-1 control and S100B transgenic mice in the dorsal, median,
and caudolinear segments of the raphe nucleus. It is pertinent to note that when all three regions were combined, the data were still not
signiﬁcantly diﬀerent (data not shown).
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Figure 3: Immunodensitometry of S100B at 10-and 28-weeks- in CD1 control and S100B transgenic mice. In (a), the S100B mice shown
signiﬁcantly (∗P<. 05) elevated S100B in CA3 stratum radiatum, the hilus, and molecular layers of the dentate gyrus. There is also a trend
towards signiﬁcance in CA1 stratum radiatum. In (b), all of these regions are signiﬁcantly elevated (∗P<. 05; ∗∗P<. 01) at the 28 week time
point.
Despite the decrease in serotonergic ﬁbers, stereological
analysis found no evidence for a decreased number of sero-
tonin neurons in the raphe nucleus, as in the human post-
m o r t e ms t u d i e so fA D( Figure 2). A recent autoradiographic
study found increased serotonin terminal density in the
substantianigra,butnotthecaudateofS100Boverexpressing
animals [72]. Therefore, changes to serotonin terminals in
S100B overexpressing mice appear to depend on the age
of the animals and on the structures examined, very much
as has been observed in human DS tissue. In the two
regions studied here, the ﬁndings suggest a loss of serotonin
neuroplasticity in the memory center, the hippocampus, but
no changes in the motor region of the caudate, which would
correlate with the human cases.
These ﬁndings show that changes in S100B could lead to
the changes in serotonin observed in DS and AD. Moreover,Cardiovascular Psychiatry and Neurology 5
S
m
a
l
l
 
M
e
d
i
u
m
 
L
a
r
g
e
 
Simple astrocytes 
Complex astrocytes 
Dysmorphic astrocytes 
CA1 
CA3 
Adolescent CD1
Adult CD1
Adolescent S100B
Adult S100B
Pyramidal  
cell layer  Molecular layer 
Granule cell layer 
Polymorphic layer 
Lacunosum moleculare 
Stratum oriens 
Dentate 
 gyrus 
Stratum radiatum 
S100B expressing astrocytes in the hippocampus
Figure 4: Schematic diagram summarizing the distribution analysis of S100B-labeled astrocytes in the hippocampus of 10 and 28-week-old
CD-1 control and S100B transgenic mice. 10 weeks: CD 1 animals showed a high density of large complex cells in CA1 SR, and a large
number of small, simple cells in CA1 LM. Although similar cell types occurred in these regions of the S100B mice, their numbers were
markedly reduced. In CA3, CD1 mice had a large number of medium to large simple cells, while the S100B mice again showed far fewer cells,
which were smaller simple cells. In addition, there were a number of small atypical cells. Again, in the dentate gyrus, the adolescent CD-
1 animals showed predominantly medium-sized complex cells, while the S100B animals showed small, simple cells. Occasionally, the S100
animalshadsmallatypicalcellswithinthepolymorphicregionofDG,whichwerevirtuallyabsentfromtheCD-1mice.ThecellsoftheS100B
animals showed pronounced “haloes” of tissue S100B-IR around all cell types of all regions, suggesting large amounts of S-100B release. A
representative photomicrograph of these ﬁndings is given in Figure 5. 28 weeks: As the CD-1 animals matured, the number of complex cells
in CA1 SR decline, but there continue to be a large number of small simple cells in LM. In CA3, the cells have become more complex. The
dentate gyrus shows fewer complex cells, more simple cells, and now the occasional complex cell is seen within the polymorphic region. In
the S100B animals, there continues to be an overall decrease in S100B-IR cells throughout the hippocampus, compared to adult CD 1 mice.
The atypical cells ﬁrst seen in adolescence are now larger and more numerous, particularly in CA3. These cells are virtually absent from the
CD-1miceatanyage.CA1cellsaresimpleofmixedsize,withanabsenceofcomplexcells.ThereareasmallnumberofcomplexcellsinCA3,
more than in adolescent S100B animals, but smaller and fewer than in CD1 adults. Cells of the DG are predominantly medium sized simple
and occasionally medium-sized complex. The atypical cells are not seen here. Again, large haloes (Figure 5) of S100B-IR are seen around the
cells.
since serotonin has long been known to be related to
depression, our ﬁndings may imply a role for S100B in
depression. S100B levels are increased in CSF and serum
of patients with depression [73, 74], and the best response
to therapy is predicted by the highest levels of S100B [75].
Selective serotonin re-uptake inhibitors are a mainstay of
treatment for depression and infants exposed prenatally to
SSRI’s have lower levels of S100B [76]. This may prove to
be a serious teratogenic eﬀect, given the role of S100B and
serotonin in brain development.6 Cardiovascular Psychiatry and Neurology
Figure 5: Photomicrograph of an S100B-positive astrocyte depict-
ing a halo (outlined by arrowheads) of S100B-positive immunos-
taining around the astrocyte. Note that the majority of adult
S100B+ astrocytes in the hippocampus of S100B transgenic mice
display this type of appearance.
Figure 6: S100B-labeling of microglial cells in the hippocampus
of 28-week-old S100B transgenic mice. In this micrograph, a rod-
shaped cell (black arrow) is shown from an adult S-100B animal.
This cell appears to be either an ependymal or microglial cell, based
on descriptions by Hortega, (1920). Other cells (white arrows) in
this photomicrograph appear to depict diﬀerent stages of microglial
diﬀerentiation. Scale bar = 20μm.
3. Neuroinﬂammation
A combination of natural aging and numerous intermittent
peaks in inﬂammatory processes, caused by environmen-
tal stressors such as infection, ischemia, or toxins, may
ultimately lead to the pathological changes associated with
aging. In the brain, these processes are termed neuroin-
ﬂammation and generally refer to those processes known
as “reactive gliosis.” That is, the accumulation of enlarged
or dystrophic microglial and astroglial cells [77]. Neuroin-
ﬂammation can then lead to loss of neurons and loss of
brain functions in a variety of neurodegenerative states [78,
79].
The role of S100B in neuroinﬂammation is becom-
ing increasingly evident [19, 80]. S100B is predominantly
expressed in astroglial cells of the mammalian nervous
system, but during neuroinﬂammatory states, the protein
can also be found in microglia [6], oligodendrocytes [1, 2],
radial glia [7], and diﬀerent classes of neurons [3, 5, 81]. In
DS, activated astrocytes are already observed in the prenatal
brain and are increasingly found with age. These increases
correlate with the number of beta-amyloid plaques [37, 38].
Activated astrocytes are also found in AD [79] and S100B
increases may play a role in their appearance. Activated
microglial cells and elevated IL-6 are observed to correlate
with elevated S100B in both disorders [82, 83]. In DS fetuses,
microglial outnumber astroglia, which is not usually the case
innormalfetuses[84].Thus,chronicinﬂammationoccursin
DS and may be involved in the inevitable, early development
of AD.
In the S100B overexpressing mice, we have looked for
eﬀects of S100B on astroglial and microglial cells, in order to
conﬁrm the role of S100B in the neuroinﬂammatory changes
seen in DS and AD. Finally, we have looked at markers of
degeneration.Theresultsofthesestudiesaredescribedinthe
following pages.
3.1. Astroglia. Astroglial appearance can generally be char-
acterized by number, cell body size, and type of processes.
Chronic overexpression of S100B results in changes to
the number and morphology of S100B-labeled astrocytes
at early (12 weeks) and later (28 weeks) timepoints. In
the S100B overexpressing mice, astroglial cells are rarely
observed to have the complex morphology with numerous
processes, which are seen in control mice. Within astroglial
cells, S100B regulates Ca2+ levels and once activated by
Ca2+, S100B interacts with intermediate ﬁlaments including
GFAP and vimentin [85, 86]. This interaction leads to
inhibition of ﬁlament polymerization, resulting in changes
to the cytoskeleton and altered astroglial morphology [87–
89]. Thus, in the S100B overexpressing animals, the excess
S100B could lead to pronounced inhibition of intermediate
ﬁlament polymerization and thus an instable cytoskeleton
that lacks multiple processes. As the S100B transgenic mice
age, the number of mature, multiprocessed S100B-labeled
astrocytes is noticeably decreased (Figure 4). Moreover,
as the transgenic animals mature, the atypical astrocytic
morphology is more pronounced, with relatively larger cell
bodies. This morphology is not observed in the control
animals at either age (see Figure 4).
It is important to note previous studies showing that at
low concentrations, S100B stimulates astroglial proliferation
[90], and at high concentrations, the protein is toxic to
astrocytes [21, 91]. Considering our ﬁndings showing that
tissue levels of S100B are elevated throughout life in the
transgenic animals (Figure 3), it is not surprising that the
astroglial cells themselves are fewer in number and have
an atypical morphology (Figure 4), changing with age. In
addition to the changes in cell morphology, it is clear by the
abundance of S100B in the parenchyma, that the astroglial
cells are releasing relatively high amounts of S-100B into
the surrounding neuropil. The released S100B is not evenly
distributedthroughouttheneuropil,butratherisconﬁnedto
characteristic “haloes” around the astroglial cell (Figure 5).
Thus, chronic elevation of S100B in DS might be one
mechanism whereby chronic astrocytic activation occurs. A
second mechanism may be through the interaction between
S100B and microglial cells.Cardiovascular Psychiatry and Neurology 7
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Figure 7: F4/80-labeling of macrophage/microglia in the CA1 pyramidal cell layer of 1-yr-old CD-1 and S100B transgenic mice. In CD-1
control animals (a), the labeling is found predominantly in resting microglial cells. Alternatively, in the S100B animals (b), several intensely
labeled cells (arrows) are observed. These cells could be activated microglia, or another type of immune cell that may have inﬁltrated the
hippocampus, such as macrophages or dendritic cells. 200X.
3.2. Microglia. Microglial cells are the primary compo-
nent of the brain’s immune system and are a key part
of neuroinﬂammatory processes [78]. As with astrocytes,
microglial cells exhibit various morphologies that correlate
with a continuum of functional states of resting, reac-
tive, chronically active and phagocytotic [92]. When the
brain is damaged, whether from seizures [93], trauma, or
diseases such as multiple sclerosis, Creutzfeldt-Jakob, DS,
and AD [94–97], microglial cells become activated [98].
Activated microglial cells proliferate [99], migrate to the
site of injury [100], alter their morphology, and begin two
important functions: initiation of inﬂammatory processes by
releaseofinﬂammatoryproteins[101–103]andphagocytosis
[104].
Microglial activation is mediated by numerous sub-
stances released by the injured tissue [105] one of which
is S100B [106]. Moreover, in pathological states, microglial
cells express S100B [6] suggesting that they may be involved
in a feedback loop. As can be seen in Figure 6, microglial
cells labeled with an antibody to S100B exhibit various
activated morphologies in adult S100B overexpressing mice.
This is consistent with in vitro studies showing that S100B
is expressed by a class of microglial cells [6]. Considering
that microglial cells are also prominent features of DS fetuses
[85], the data support the idea that S100B overexpression
inﬂuences microglial cells during development and in adult-
hood.
S100B has been shown to have at least two eﬀects on
microglial cells, one of which (production of nitric oxide)
is RAGE-independent whereas the other (increases in the
transcription factor NFkappaB) is dependent on binding
to microglial RAGE [107]. When S100B binds to RAGE,
the microglial cells become activated. Thus, chronic S100B
elevation may inﬂuence chronic microglial activation via
this mechanism. Support for this idea is derived from the
fact that binding of ligands to RAGE leads to activation
of signaling pathways which in turn can modulate gene
expression [108] .O n es u c hp a t h w a ya c t i v a t e di st h a to f
the proinﬂammatory transcription factor, NFκB, which
regulates cytokines, including interleukin IL-1, IL-6, and
t u m o rn e c r o s i sf a c t o r[ 109, 110].
Both control and S100B-overexpressing animals show
an increase in microglial cells and RAGE expression with
age. However, this eﬀect is more pronounced in the S100B
animals, [46] (also see Figure 7). Thus, S100B binding to
microglial RAGE may be a second mechanism whereby
chronic S100B elevation in DS exacerbates chronic neuroin-
ﬂammation.
3.3. Neuroinﬂammation and Neurodegeneration. Although a
role linking S100B directly to cell death in DS and AD has
not been established, there is evidence from animal data that
this may indeed be the case [111, 112]. S100B transgenic
animals show neuronal loss and increased expression of the
proapoptotic protein clusterin [48] which is also increased
in hippocampus and frontal cortex of AD [113]. In addition,
previous animal studies have shown that using arundic acid
to negatively regulate S100B will ameliorate beta-amyloid
deposits, plaques, and glial (astrocyte and microglial) hyper-
trophy [114]. Interestingly, recent ﬁndings in the S100B
transgenic mice show that S100B overexpression can lead
to increases in the hyperphosphorylated tau protein found
in neuroﬁbrillary tangles (Figure 8). In a mouse model of
AD, chronic over-expression of S100B has been shown to
intensify gliosis and amyloidosis [115]. Moreover, chronic
over-expression of human S100B increases brain damage
and peri-infarct gliosis after focal ischemia. Together, these
data support the idea that high levels of S100B can be
detrimental in neuropathological conditions. Considering
these ﬁndings, the S100B transgenic mice could be used to
provide insight into possible prevention and treatments, for
plaques, tangles, or other neuropathologies associated with
S-100B overexpression.
For example, Vitamin E was examined in the S100B
overexpressing mouse to determine if antioxidant treatment
had the potential to attenuate neuroinﬂammatory damage
associated with increased S100B. The results show that
although Vitamin E decreased microglial activation in the
control animals, it actually increased microglial activation
andRAGEexpressioninS100Boverexpressingmice[46].We
and others [53, 74] have hypothesized that in the state of8 Cardiovascular Psychiatry and Neurology
(a) (b) (c)
Tau immunoreactivity in the hippocampus of 1yr old S100B transgenic mice
Figure 8: Tau-2-IR in the hippocampus of a one-year-old S100B transgenic animal. The antibody used in these studies recognizes
a hyperphosphorylated form of tau usually associated with neuroﬁbrillary tangles. In the developing brain, S100B promotes neurite
outgrowth. However, in a brain chronically exposed to elevated levels of S100B, the neurites become dystrophic. (a) Cell body staining in
pyramidal neurons of CA3, presumably to intracellular neuroﬁbrillary tangles, 400X. (b) Neuropil threads in the lower blade of the dentate
gyrus showing axonal accumulation of tau-2-IR, 600X. (c) Neuritic plaque in CA1 of stratum radiatum. This is a dense accumulation of
neuriticﬁbers,similartothatdescribedforthisantibodyinhumanADsubjects,associatedwithhighlevelsofS100B(Shengetal.[82]),600X.
chronic overexpression of S100B, oxidation of S100B serves
to preferentially induce the neurotrophic properties over
the neuroinﬂammatory processes. Thus, treatment with an
antioxidant to an animal already over-expressing S100B may
interrupt this feedback, leading to further increases in RAGE
upregulation and glial activation. Vitamin E may appear to
be beneﬁcial in a control animal, but animals already overex-
pressing S100B may show an increase in neuroinﬂammatory
processes as evidenced by increased microglial activation
[46]. This study makes the important point that studying
potential treatments to prevent neurodegeneration should
be done in animals which resemble the human form of
neuropathology.
4. Conclusion
In conclusion, the data demonstrate that chronic S-100B
overexpression results in serotonergic ﬁber alterations in the
hippocampus, but no alterations to the number of serotonin
neurons in the raphe nuclei. The data also show that
chronic S100B over-expression results in activated astrocytes
and microglia beginning during neonatal development and
persisting through adulthood. Such changes are associated
with an increase in RAGE expression. Considering the
appearance of TAU-immunolabeling as a result of chronic
S100B overexpression, future studies are needed to better
understand the role of S-100B in mediating serotonergic and
glial alterations, and their role in neuropathologies, such as,
DS, aging, and AD.
Appendix
A. Methods
A.1. Animals. Male S-100B transgenic mice, aged 10 weeks
(N = 4–6) and 28 weeks (n = 4–6) were compared to age
matched, 10-week-old congenic CD-1 (N = 4–6) and 28
week CD-1 (N = 4–6) control mice. The S-100B mice and
their congenic CD1 controls used in this study, were raised
in the animal care facilities at SUNY Stony Brook, under
identical conditions, of 12/12 light/dark cycle with food and
w a t e rp r o v i d e da dl i b i t u m .
A.2. Immunocytochemistry. All animals were perfused with
50 mL of .9% saline followed by 50 ml of 4% paraformalde-
hyde ﬁxative. Brains were extracted and post ﬁxed in 4%
PLP for one hour. The brains were then cryoprotected
successively in 10%, 20%, and 30% sucrose, each for twenty-
four hours. Following cryoprotection, brains were sectioned
on a freezing microtome at 40um. Each group consisted
of four to six male mice. For immunostaining, the tissue
was ﬁrst blocked in 1% peroxide for 1hour and then
blocked with 3% goat serum and .03% triton-X, in PBS
for 1hour. The tissue is then incubated free ﬂoating, in
primary antibody (S100B, Sigma; 5-HTT 1:1000, generous
gift from Dr. Feng Zhou, University of Indiana; 5-HT,
1:200, sigma #S5545; F4/80, 1:1000, Serotec MCA497R;
Tau2, 1:500, Sigma #T5530), with 3% normal goat serum
and .3% triton-X100, on a cold rotator (4C), for twenty
four hours. Tissue was then rinsed in PBS and rotated for
1.5 hour, at room temperature, free ﬂoating in secondary
IgG (Sigma, 1:200) raised against the appropriate species
speciﬁc for each primary antibody, in PBS with 3% normal
goat serum and .3% triton-X100. Next, the tissue was rinsed
in PBS and incubated in Vectastain elite avidin biotin
complex (Vector, Burlingame, CA), for one hour, rotating
at room temperature. Negative control sections were carried
out simultaneously, following the same protocol, minus the
primary antibodies. The antibody complex was visualized
using .05% diaminobenzadine (DAB), with 30% peroxidase
added after the tissue soaked for 3minutes. Tissue was
rinsed and mounted onto gelatin coated slides, dehydrated
inalcohol,clearedinxylene,andcoverslipswereappliedwith
permount.
Slides were coded and all images were captured on an
Olympus BH-2 microscope, with a Tripix digital camera.Cardiovascular Psychiatry and Neurology 9
Images were saved on a windows-based computer. In all
instances, data was analyzed by raters blind to the condition
of the animals.
A.3. Serotonin Transporter Analysis. Estimates of the surface
density (Sv) of SERTir ﬁbers were obtained using the cycloid
grid intercept method [116]. This method is based on
Buﬀoun’s needle principal [117], which states that the length
of a object (a needle in Buﬀon’s case, SERTir ﬁbers in
this experiment) is directly proportional to the number of
random intersections it makes with lines on a grid and
inversely proportional to the distance separating the lines
on the grid. Mathematically this relationship is described as
P = (2/pi) × (l/d), where P is the probability of an object-
line intersection, 2/pi encompasses all possible angles of
intersection between the object and the line, l is the length of
the objectgh and d is the distance separating the lines on the
grid. Cycloids are used in this experiment rather than a strait
line grid, because in the case of the serotonin transporter
ﬁbers, the ﬁbers are curved and transverse through multiple
orientations of the three-dimensions of the tissue. Thus,
the cycloid grid compensates for bias created by the cutting
orientation [116]. For this experiment, a counting frame
with 16 cycloid test lines, each with a length of 21uM, was
superimposed over photomicrographs of the infrapyramidal
granule cell layer of the dentate gyrus, which was chosen as
thehorizontalorientationpoint.Foreachanimal,thecycloid
grid was superimposed over an area of molecular layer of the
infrapyramidal blade of the dentate gyrus and intersections
betweenthecycloidlinesandSERTirﬁberswerecounted.For
each animal, 5 images separated by 240uM were analyzed,
corresponding to Paxino and Franklin plates 41–50 in the
m o u s eb r a i na t l a s[ 118]. At the ﬁnal magniﬁcation (600X),
the total cycloid length for the grid was 336μM. Surface
density (Sv) was calculated using the equation Sv = 2 ×
PL, where Sv is the surface area per unit volume of tissue,
and PL is total number of intersections, divided by the total
length of the probe. A ﬁber was considered to be in the
plane of focus if it was not blurry. In order to insure the
accuracy of scoring, three blind raters were given the same
setofinstructionsforwhatconstitutedacycloidintersection.
The data were compared using regression analysis and once
veriﬁed, the three scores for each image were averaged, to
yield the average intersections per image. These averages are
used to calculate Sv, which is expressed as CM2 of SERTir
ﬁbers, per CM3 of tissue (CM2/CM3). The average Sv for
eachanimalwasenteredintoSPSS(version9.0)andanalyzed
usingtheunivariateanova,withconditionasﬁxedfactorand
surface density of SERT ir ﬁbers, the dependant variable.
InadditiontothestereologicalanalysisofSERTﬁbers,we
also performed a densitometric analysis of SERT containing
processes using the University of Texas Image Tool program
(V. 3.0). Using the threshold setting, the images were
assigned a pixel value within which the SERT ﬁbers would be
transformed into black pixels and the surrounding neuropil
would be transformed into white pixels. This method
allowed us to identify only the ﬁbers which stained intensely
enough to fall within the threshold range, which were
presumed to be those ﬁbers within the range of the plane of
focus of the objective lens (Olympus 60X, aperture = .90).
The number of black and white pixels was then quantiﬁed
using the ImageTool program, which digitally automates the
counting. For each animal, 5 images were examined from the
infrapyramidal blade of the dentate gyrus and averaged, to
yield a percentage of black pixels per animal. The averages
for each animal were analyzed using the univariate Anova on
SPSS (version 9.0).
This method proved to be reliable and consistent with
the stereological probe technique in the dentate gyrus.
Thus, additional photomicrographs were examined using
this technique in the following hippocampal areas: CA1,
CA3, stratum radiatum, and lacunosum molecular.
A.4. Analysis of 5-HT Cells in the Adult Raphe Nucleus.
The staining protocol was as above, except, the primary
antibody was incubated for forty-eight hours. Raphe nucleus
sections, separated by 40uM, containing 5-HTir neurons,
were included for cell counts. Images were captured as stated
above, and neurons were counted by a blind scorer. Neurons
were counted in a 1.058mm2 area, containing the dorsal,
median, or caudolinear raphe nucleus. The sum of 5-HTir
neurons counted for each region was divided by the sum of
the number of images counted, to yield an average density of
5-HTir neurons in a 1.058mm2 area. The data was analyzed
using a multivariate analysis of variance, with condition as
theﬁxedfactor,andthedorsal,median,orcaudolinearraphe
nucleus as the dependant variables.
A.5. Detailed Morphological Analysis of S100B-Labeled Cells.
Detailed morphological analysis of S-100B immunoreactive
(IR) glial cells in the hippocampus was performed by
raters blind to the age and genetic background of the
animals.Withinthehippocampus,thepredominantcelltype
expressing S-100B IR are astrocytes of varying morphology.
The morphology of the astrocytes was deﬁned based on
the size of the cell body, complexity of processes, and
approximate number. Size: cells were deﬁned as small, if
cell bodies were less than 4μm, medium at 4–8μm, and
large if the cell body was greater than 8μm. Processes: cells
were classiﬁed as simple (no signiﬁcant processes, similar
to cells described as “protoplasmic,” immature or Type I),
complex (many ramiﬁed processes, arranged symmetrically
around the cell body, similar to “stellate” or “ﬁbrous”),
or atypical (cells with nonsymmetrical processes, such as
one large think process). Number: cell density was deﬁned
as sparse, moderate, or dense based on their relative
appearance. Hippocampal subﬁelds: in general, area CA2
represented a homogenized zone between CA3 and CA1,
demonstratingimmunoreactivityforthetypesofcellsseenin
both regions. Thus, only areas CA1 and CA3 were analyzed.
When referring to CA3 lacunosum moleculare (LAC), this
represents the area of LAC which is adjacent to CA3/CA2
region. The rest of LAC is considered to be in the CA1
region. In the dentate gyrus, the morphological appearance
of the supra and infrapyramidal blades of the molecular
layer of the dentate gyrus was indistinguishable, and thus
these are classiﬁed together. The following abbreviations are10 Cardiovascular Psychiatry and Neurology
used to describe the hippocampal subﬁelds: Pyramidal Cell
Layer (PYR); Stratum radiatum (SR); Stratum oriens (SO);
Lacunosum Moleculare (LAC); Dentate Molecular layers
(MOL); Dentate Granule cell layer (DGN); Polymorphic
zone (PMZ).
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